跳至主要内容
临床试验/NL-OMON41680
NL-OMON41680招募中3 期

A randomized controlled trial into the efficacy of neurofeedback for treatment of major depressive disorder - Neurofeedback for depression

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Primary axis-1 disorder of Major Depressive Disorder fulfilling DSM-IV-TR criteria.
  • Written informed consent.

排除标准

  • History of brain trauma (commotio or contusio cerebra) or CVA
  • Current use of antipsychotics, moodstabilizers or benzodiazepines. Current use of antidepressants is permitted if this medication is not changed within a period of 6 weeks prior to participation in the study. Additionally, no changes in antidepressant medication are allowed during active participation in the study.
  • Chronic depression (> two years duration).
  • Dysthymia as a primary axis-1 diagnosis
  • Bipolar disorder or schizophrenia as a primary axis-1 diagnosis
  • Severe suicidality (HDRS item # 3 with a score >2) or severe depression symptomatology (HDRS score > 25).
  • Pregnancy.
  • Age < 18 years.
  • Daily alcoholintake of >7 units.

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验